Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant Hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    113 result(s) found for: Malignant Hypertension. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2012-002927-14 Sponsor Protocol Number: AGO/2012/004 Start Date*: 2013-07-10
    Sponsor Name:University Ghent
    Full Title: Dosistitratie van lisinopril bij kinderen van 1 tot 18 jaar met primaire of secundaire hypertensie
    Medical condition: Hypertensie
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020781 Hypertension malignant LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001863-35 Sponsor Protocol Number: THAM Start Date*: 2016-06-21
    Sponsor Name:Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien
    Full Title: Effects of Tromethamine on Cerebral Oxygenation and Metabolism in Patients Suffering Intractable Intracranial Hypertension – an exploratory study.
    Medical condition: Critically ill patients (SAH, ICB, AVM bleedings, malignant MCA infarcts) under sedation and mechanical ventilation in need of multimodality monitoring, including brain tissue oxygen monitoring and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001020-35 Sponsor Protocol Number: 94070C Start Date*: 2012-12-05
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: A randomized phase II trial comparing bevacizumab monotherapy with dacarbazine (DTIC) in treatment of malignant melanoma, focusing on angiogenic markers and prevention of hypertension.
    Medical condition: Previously treated or untreated histologically confirmed metastatic and unresectable melanoma with radiological (RECIST), clinical or biochemical progressive disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001861-40 Sponsor Protocol Number: BRTA-0100-015 (EORTC 62061) Start Date*: 2006-09-21
    Sponsor Name:SYSTEMS MEDICINE, LLC
    Full Title: Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
    Medical condition: Advanced or metastatic soft tissue sarcoma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002695-34 Sponsor Protocol Number: CS-201 Start Date*: 2009-01-23
    Sponsor Name:Kringle Pharma Europe AB
    Full Title: A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of ChronSeal® (5-amino-acid deleted recombinant human Hepatocyte Gr...
    Medical condition: Non-malignant full skin chronic venous leg ulcers of an area 3 - 20 cm2.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047260 Venous ulceration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000053-30 Sponsor Protocol Number: A4061016 Start Date*: 2005-07-21
    Sponsor Name:Pfizer Inc. - La Jolla laboratories
    Full Title: A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portion
    Medical condition: Treatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreas
    Disease: Version SOC Term Classification Code Term Level
    5.1 10033604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005993-39 Sponsor Protocol Number: IPR/16 Start Date*: 2007-04-26
    Sponsor Name:MOLMED
    Full Title: NGR010: A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than on...
    Medical condition: patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeutic
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035605 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004909-33 Sponsor Protocol Number: LCTU122 Start Date*: 2015-09-21
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Thrombin Inhibition Preoperatively in Early Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002525-29 Sponsor Protocol Number: UC-0140/1206 Start Date*: 2013-03-08
    Sponsor Name:UNICANCER
    Full Title: A phase II trial evaluating the Activity of Abiraterone Acetate plus Prednisone in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.
    Medical condition: Molecular apocrine locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000774-58 Sponsor Protocol Number: E7050-703 Start Date*: 2012-01-30
    Sponsor Name:Eisai Inc.
    Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cisplatin and Capecitabine versus Cisplatin and Capecitabine Alone in Patients with Advanced or Metastatic Sol...
    Medical condition: Advanced or metastatic solid tumors and previously untreated gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003043-29 Sponsor Protocol Number: MITO-16/MaNGO-OV2 Start Date*: 2012-09-24
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: A multicenter study in patients with stage III-IV epithelial ovarian cancer treated with carboplatin/paclitaxel with bevacizumab: clinical and biological prognostic factors
    Medical condition: advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001770-19 Sponsor Protocol Number: TUD-SplusL-061 Start Date*: 2014-09-01
    Sponsor Name:Technische Universität Dresden
    Full Title: 6 month, multi-center, open-label, prospective, randomized trial, investigating a standard regimen of an advagraf based immunosuppressive regimen in de-novo renal transplant patients versus a sl...
    Medical condition: patients, waiting for first or second renal transplantation de novo kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10038474 Renal insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007792-24 Sponsor Protocol Number: 1.1 Start Date*: 2009-03-13
    Sponsor Name:Medical University of Graz, Department of Internal Medicine, Div. Endocrinology and Nuclear Medicine
    Full Title: Effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters
    Medical condition: Healthy volunteers. The intended indication for the product under development is prevention and treatment of immunological (e.g. type 1 diabetes), endocrine (e.g. endocrine hypertension) metabolic ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005732-27 Sponsor Protocol Number: UCSC-OM-SU-01 Start Date*: 2006-12-21
    Sponsor Name:Policlinico Universitario Agustino Gemelli
    Full Title: EFFICACY AND SAFETY OF THE MULTITARGET INHIBITOR AGENT SU11248 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
    Medical condition: Advanced (localized disease but surgically unresectable or metastatic) histologically/cytologically proven hepatocellular carcinoma (or hepatic lesion and aFP ³ 400 ng/ml).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007284 Carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005887-97 Sponsor Protocol Number: MO19390 Start Date*: 2006-07-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer
    Medical condition: Advanced or recurrent non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9 10059515 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) SE (Completed) ES (Completed) NL (Completed) AT (Completed) CZ (Completed) EE (Completed) DE (Completed) LT (Completed) HU (Completed) SK (Completed) GB (Completed) PT (Completed) DK (Completed) LV (Completed) IS (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017485-23 Sponsor Protocol Number: EORTC90091-10093 Start Date*: 2013-04-24
    Sponsor Name:EORTC
    Full Title: TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)
    Medical condition: HER2-Negative Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) DE (Completed) GR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002069-22 Sponsor Protocol Number: ET17-057 Start Date*: 2018-04-18
    Sponsor Name:CENTRE LEON BERARD
    Full Title: BREASTIMMUNE02 - A multicenter, randomized, open-label, Phase II trial aiming to evaluate the impact of pegfilgrastim on trastuzumab anti-tumor effect and antibody-dependent cell-mediated cytotoxic...
    Medical condition: Operable HER2 positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006188 Breast cancer female NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001568-66 Sponsor Protocol Number: A4061028 Start Date*: 2007-08-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Full Title: A randomized, double-blind phase 3 study of gemcitabine plus AG-013736 versus gemcitabine plus placebo for the first-line treatment of patients with locally advanced, unresectable or metastatic pan...
    Medical condition: Unresectable or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SE (Completed) GB (Prematurely Ended) FR (Completed) PT (Completed) AT (Prematurely Ended) HU (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000961-10 Sponsor Protocol Number: NITRO Protocol Start Date*: 2011-12-07
    Sponsor Name:Royal Liverpool and Broadgreen University Hospitals Trust
    Full Title: Neoadjuvant IntraviTreal Ranibizumab treatment in high risk Ocular melanoma patients: A two stage single centre Phase II single arm study (NITRO Trial)
    Medical condition: Uveal Melanoma (requiring enucleation)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020385-13 Sponsor Protocol Number: 52702928 Start Date*: 2010-06-21
    Sponsor Name:Vejle Hospital
    Full Title: Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations
    Medical condition: Inoperable cholangiocarcinoma without KRAS mutations
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA